Harrison, Stephen A.
Gunn, Nadege
Neff, Guy W.
Kohli, Anita
Liu, Liping
Flyer, Abbey
Goldkind, Lawrence
Di Bisceglie, Adrian M. http://orcid.org/0000-0002-6075-9305
Funding for this research was provided by:
HighTide Therapeutics
Article History
Received: 24 February 2021
Accepted: 24 August 2021
First Online: 17 September 2021
Competing interests
: The authors listed below have the following competing interests: S.A.H.: Reports grant/research support from Axcella, BMS, Cirius, CiVi, Conatus, Cymabay, Enyo, Galectin, Galmed, Genentech, Genfit, Gilead, Hepion, Hightide, Intercept, Inventiva, Madrigal, NGM Bio, Northsea, Novartis, Novo Nordisk, Pfizer, Sagimet, and Viking. Consulting fees from Akero, Altimmune, Arrowhead, Axcella, Canfite, Cirius, CiVi, CLDF, Cymabay, Echosens, Fibronostics, Foresite Labs, Galectin, Genfit, Gilead, Hepion, Hightide, HistoIndex, Intercept, Kowa, Madrigal, Metacrine, NGM Bio, Novartis, Novo Nordisk, Poxel, Ridgeline, Sagimet, Terns, and Viking. N.G.: Research grants: Axcella, BMC, CymaBay, Genetech, Genfit, Gilead, High Tide, Madrigal, North Sea, NGM Bio, Novo Nordisk; Consultant/Speaker: AbbVie, Dova, Gilead, Intercept, Salix. G.W.N.: Grants: Ecosens, Intercept. Consultant/Speaker: Gilead, Intercept, Salix. A.K.: Grant/research support from Axcella, BMS, Cirius, Conatus, Cymabay, Enyo, Galectin, Genentech, Genfit, Gilead, Hightide, Intercept, Madrigal, NGM Bio, Northsea, Novartis, Novo Nordisk, Pfizer, Poxel, and Viking. Consulting fees from Intercept and Gilead. L.L.: employee of HighTide Therapeutics. A.F.: independent contractor to HighTide. L.G.: is a consultant to HighTide. A.M.D.: is a consultant to HighTide and Chief Medical Officer.